Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib

International Journal of Clinical Oncology

Volumn 17, Issue 2, 2012, Pages 155-159

  Tetsumoto, Satoshi ^a   Osa, Akio ^a   Kijima, Takashi ^a   Minami, Toshiyuki ^a   Hirata, Haruhiko ^a   Takahashi, Ryo ^a   Kuhara, Hanako ^a   Nagatomo, Izumi ^a   Takeda, Yoshito ^a   Kida, Hiroshi ^a   Goya, Sho ^a   Tachibana, Isao ^a   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood brain barrier; Epidermal growth factor receptor; Erlotinib; Gefitinib; Leptomeningeal metastases; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; ERLOTINIB; GADOLINIUM; GEFITINIB; PACLITAXEL;

ADULT; ARTICLE; BONE METASTASIS; BRAIN VENTRICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CONTRAST ENHANCEMENT; DEATH; DISEASE EXACERBATION; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; MENINGEAL METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; URINE RETENTION; VOMITING;

BLOOD-BRAIN BARRIER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MENINGEAL NEOPLASMS; MIDDLE AGED; QUINAZOLINES;

EID: 84862867691     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0256-9     Document Type: Article

References (17)

1. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomato-sis. Cancer Treat Rev 25:103-119
2. Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344-2348
3. Namba Y, Kijima T, Yokota S et al (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6:123-128
4. Gurpide A, Perez-Gracia JL, Lopez-Picazo JM et al (2005) Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature. Clin Lung Cancer 7:138-140
5. Fidler IJ, Yano S, Zhang RD et al (2002) The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3:53-57
6. Stewart DJ, Leavens M, Maor M et al (1982) Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42:2474-2479
7. Postmus PE, Smit EF (1999) Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 10:753-759
8. Minotti V, Crino L, Meacci ML et al (1998) Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 20:93-98
9. Bernardo G, Cuzzoni Q, Strada MR et al (2002) First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 20:293-302
10. Jackman DM, Holmes AJ, Lindeman N et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517-4520
11. Broniscer A, Panetta JC, O'Shaughnessy M et al (2007) Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 13:1511-1515
12. Togashi Y, Masago K, Fukudo M et al (2010) Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 5:950-955
13. Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80-84
14. Katayama T, Shimizu J, Suda K et al (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415-1419
15. Choong NW, Dietrich S, Seiwert TY et al (2006) Gefitinib response of erlotinib-refractory lung cancer involving menin-ges-role of EGFR mutation. Nat Clin Pract Oncol 3:50-57
16. Tang Z, Jiang S, Du R et al (2009) Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene 28:518-533
17. Tsuchiya K, Katase S, Yoshino A et al (2001) FLAIR MR imaging for diagnosing intracranial meningeal carcinomatosis. Am J Roentgenol 176:1585-1588